1. Resilienzmanagement in KMU: Wie Unternehmen strategisch und widerstandsfähig agieren
132 results on '"Weber, Holger"'
Search Results
2. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells
3. Abstract 4148: Immunophenotyping of responses to immunotherapy in syngeneic tumor models using multiplex immunofluorescence compared to multiparametric flow cytometry
4. Abstract 671: Exploiting macrophage differentiation and plasticity as an immunomodulating strategy
5. Abstract 4419: Use of luciferase-labeled target cells to explore immune cell killing in high throughput format in 2D and 3D co-cultures
6. Abstract 33: Humanized MOLM-13 AML model as a versatile tool to study immune-activating agents
7. Abstract 5194: Humanized PD-1 knock-in mice as a model system for combination therapies with human specific PD-1 therapeutics
8. Low-Cost Synchronization Techniques for KUKA Robots and External Axes in Low-Dynamic Processes
9. Targeting hormone refractory prostate cancer by in vivo selected DNA libraries in an orthotopic xenograft mouse model
10. Cell Lines Expressing Recombinant Transmembrane Domain–Activated Receptor Kinases as Tools for Drug Discovery
11. Abstract 1621: Comparison and consequences of different implantation techniques on the orthotopic growth of syngeneic Hepa1-6 liver cancer cells
12. Abstract 2318: Real-time quantitative PCR based analysis of transcriptional effects of CDK8/Cyclin C inhibitors
13. Abstract 629: Benefit of using a spectral flow analyzer for the analysis of immune cell populations in tumors
14. Antitumor activity of vanadocene Y and its selenocyanate derivative in xenografted caki-1 tumors in mice
15. Depression of progenitor cell function by advanced glycation endproducts (AGEs): Potential relevance for impaired angiogenesis in advanced age and diabetes
16. The Antiangiogenic and Antitumoral Activity of Titanocene Y* In Vivo
17. Abstract A012: Mammary fat pad injections: An alternative implantation method for syngeneic tumor models
18. The Potency of Refined Mouse Models: Implications for Clinical Trials
19. Abstract 495: All-in-one flow cytometry staining panel for immune-cell profiling in syngeneic tumor models
20. Abstract 341: Synergy of FLT3 inhibitors and a small molecule inhibitor of LIM kinase1/2 in FLT3-ITD positive acute myeloblastic leukemia (AML)
21. Extraction of more than 10kW from a single ytterbium-doped MM-fiber
22. Mouse-Derived Isograft (MDI) In Vivo Tumor Models II. Carcinogen-Induced cMDI Models: Characterization and Cancer Therapeutic Approaches
23. Mouse-Derived Isograft (MDI) In Vivo Tumor Models I. Spontaneous sMDI Models: Characterization and Cancer Therapeutic Approaches
24. Abstract 5683: Value of new spontaneous and carcinogen-induced mouse-derived isograft (MDI) tumor models for drug development of novel immune therapeutic approaches
25. Abstract 1156: New spontaneous and carcinogen-induced mouse-derived isograft (MDI) tumor models for immune therapeutic approaches
26. Fully integrated Q-switch for commercial high-power resonator with solitary XLMA-fiber
27. Abstract A014: Evaluation of the hollow fiber model as a highly predictive in vivo testing system for the selection of xenograft tumor models in cancer drug discovery
28. Abstract 3216: Anti-PD-1, Anti-PD-L1 and Anti-CTLA-4 checkpoint inhibitor treatment leads to different responses in syngeneic tumor models
29. Abstract A16: Boosting of in vivo hollow fiber assay by using luciferase-labeled tumor cell lines
30. Abstract B139: Determination of the plasma inhibitory activity of drugs using cellular kinase assays
31. Abstract 5010: A versatile tool to study immune checkpoint therapeutics: Syngenic tumor mouse models in vivo
32. Abstract 3377: Co-spheroid analysis reveals attenuating effect of HS27A stroma cells on DLD1 colon carcinoma susceptibility to MEK kinase inhibitor trametinib
33. Endothelial cell spheroids as a versatile tool to study angiogenesisin vitro
34. Abstract 2026: Analysis of the impact of compounds derived from marine organisms on 3D co-spheroids generated from multiple myeloma cells and stromal cell types
35. Abstract C109: Discovery of new natural anti-tumoral compounds using a parallel target- and phenotypic-driven screening approach.
36. Abstract 1554: Inducible B-Raf and c-Src models as tools for drug development.
37. Analyses of Titanocenes in the spheroid-based cellular angiogenesis assay
38. Abstract 5681: A high throughput soft agar assay on a panel of 60 tumor cell lines to study compounds for potential anti-oncogenic properties
39. Abstract A141: Analysis of cellular kinase activity of resistance-related MET mutants using transmembrane-domain (TMD) activated kinase variants.
40. Gamma-Secretase Inhibitor Treatment Promotes VEGF-A-Driven Blood Vessel Growth and Vascular Leakage but Disrupts Neovascular Perfusion
41. Abstract 5434: Functional screening for impact on cancer hallmarks migration, transformation and angiogenesis identifies potential new drug leads isolated from marine organisms
42. Differential Endothelial Transcriptomics Identifies Semaphorin 3G as a Vascular Class 3 Semaphorin
43. Identification of 2-Anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as Dual PLK1/VEGF-R2 Kinase Inhibitor Chemotypes by Structure-Based Lead Generation
44. Spheroid-based human endothelial cell microvessel formation in vivo
45. Combination of Reverse and Chemical Genetic Screens Reveals Angiogenesis Inhibitors and Targets
46. Dimensioning of secondary and tertiary control reserve by probabilistic methods
47. Antitumor Activity of Oxali-Titanocene Y in Xenografted CAKI-1 Tumors in Mice
48. In Vitro and in Vivo Evaluation of Doxorubicin Conjugates with the Divalent Peptide E-[c(RGDfK)2] that Targets Integrin αvβ3
49. Spheroid-based engineering of a human vasculature in mice
50. Accuracy and clinical implications of seven 25-hydroxyvitamin D methods compared with liquid chromatography–tandem mass spectrometry as a reference
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.